Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: A cost-effectiveness analysis

Respiratory Research

Volumn 15, Issue 1, 2014, Pages

  Van Boven, Job F M ^a   Tommelein, Eline ^b   Boussery, Koen ^b   Mehuys, Els ^b   Vegter, Stefan ^a   Brusselle, Guy G O ^c,d   Rutten van Mölken, Maureen P M H ^e   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Adherence; Cost effectiveness; Inhalation technique; Intervention; Pharmacist

Indexed keywords

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; INHALATION; INHALER; LONG TERM CARE; MALE; MEDICATION COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; MULTICENTER STUDY; NEBULIZER; PHARMACY; STANDARD;

COMMUNITY PHARMACY SERVICES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84902044841     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-15-66     Document Type: Article

References (47)

1. World Health Organization Chronic obstructive pulmonary disease. http://www.who.int/respiratory/copd/en, World Health Organization.
2. van Boven JF, Vegter S, van der Molen T, Postma MJ. COPD in the working age population: the economic impact on both patients and government. COPD 2013, 10(6):629-639. 10.3109/15412555.2013.813446, 23845002.
3. Scientific Institute for Public Health Belgium (WIV-ISP). https://www.wiv-isp.be.
4. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2013, http://www.goldcopd.org.
5. Mehuys E, Boussery K, Adriaens E, Van Bortel L, De Bolle L, Van Tongelen I, Remon JP, Brusselle G. COPD management in primary care: an observational, community pharmacy-based study. Ann Pharmacother 2010, 44(2):257-266. 10.1345/aph.1M481, 20103611.
6. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, Serra M, Scichilone N, Sestini P, Aliani M, Neri M, . Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011, 105(6):930-938. 10.1016/j.rmed.2011.01.005, 21367593, Gruppo Educazionale Associazione Italiana Pneumologi Ospedalieri.
7. van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med 2014, 108(1):103-113. 10.1016/j.rmed.2013.08.044, 24070566.
8. Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernandez C, Alonso A, del Pozo F, de Toledo P, Anto JM, Rodriguez-Roisin R, Decramer M, . Members of the CHRONIC Project Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006, 28(1):123-130. 10.1183/09031936.06.00063205, 16611656, Members of the CHRONIC Project.
9. Takemura M, Mitsui K, Ido M, Matsumoto M, Koyama M, Inoue D, Takamatsu K, Itotani R, Ishitoko M, Suzuki S, Aihara K, Sakuramoto M, Kagioka H, Fukui M. Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients. Int J Chron Obstruct Pulmon Dis 2013, 8:239-244. 3656647, 23696699.
10. Jarab AS, Alqudah SG, Khdour M, Shamssain M, Mukattash TL. Impact of pharmaceutical care on health outcomes in patients with COPD. Int J Clin Pharm 2012, 34(1):53-62. 10.1007/s11096-011-9585-z, 22101426.
11. Tommelein E, Mehuys E, Van Hees T, Adriaens E, Van Bortel L, Christiaens T, Van Tongelen I, Remon JP, Boussery K, Brusselle G. Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol 2014, 77(5):756-766. 10.1111/bcp.12242, 24117908.
12. Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken MP. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective?. Eur Respir J 2010, 35(1):79-87. 10.1183/09031936.00043309, 19574331.
13. Steuten LM, Lemmens KM, Nieboer AP, Vrijhoef HJ. Identifying potentially cost effective chronic care programs for people with COPD. Int J Chron Obstruct Pulmon Dis 2009, 4:87-100. 2672791, 19436687.
14. Boland MR, Tsiachristas A, Kruis AL, Chavannes NH, Rutten-van Molken MP. The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis. BMC Pulm Med 2013, 13:40. 2466-13-40, 10.1186/1471-2466-13-40, 3704961, 23819836.
15. Bryant J, McDonald VM, Boyes A, Sanson-Fisher R, Paul C, Melville J. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res 2013, 14(1):109. 10.1186/1465-9921-14-109, 4015036, 24138097.
16. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006, 40(7-8):1280-1288.
17. Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. Pharmacoeconomics 2012, 30(9):825-840. 10.2165/11591340-000000000-00000, 22799876.
18. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005, 8(1):32-46. 10.1111/j.1524-4733.2005.03086.x, 15841892.
19. Starkie HJ, Briggs AH, Chambers MG. Pharmacoeconomics in COPD: lessons for the future. Int J Chron Obstruct Pulmon Dis 2008, 3(1):71-88. 2528220, 18488430.
20. Rutten-van Molken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics 2012, 30(4):271-302. 10.2165/11589270-000000000-00000, 22409290.
21. Cleemput I, Crott R, Vrijens F, Huybrechts M, Van Wilder P, Ramaekers D. Voorlopige richtlijnen voor farmaco-economisch onderzoek in België 2006, Brussels: Belgian Health Care Knowledge Centre (KCE). KCE reports 28A, Health Technology Assessment (HTA), D2006/10.273/10.
22. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Molken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010, 5:435-444. 3008329, 21191438.
23. Belgisch Centrum voor Farmacotherapeutische Informatie (B.C.F.I. VZW). http://www.bcfi.be.
24. Oostenbrink JB, Rutten-van Molken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004, 98(9):883-891. 10.1016/j.rmed.2004.02.013, 15338802.
25. Neyt M, Van den Bruel A, Gailly J, Thiry N, Devriese S. Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: Health Technology Assessment 2009, Brussels: Belgian Health Care Knowledge Centre (KCE). KCE reports 108C, Health Technology Assessment (HTA), D/2009/10.273/20.
26. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC, Sullivan SD. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 2004, 7(2):153-167. 10.1111/j.1524-4733.2004.72318.x, 15164805.
27. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, Al MJ, Feenstra TL. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease. Value Health 2011, 14(8):1039-1047. 10.1016/j.jval.2011.06.008, 22152172.
28. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, Feenstra TL. A dynamic population model of disease progression in COPD. Eur Respir J 2005, 26(2):223-233. 10.1183/09031936.05.00122004, 16055869.
29. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. the lung health study. Am J Respir Crit Care Med 2000, 161(2 Pt 1):381-390.
30. Wysocki T, Greco P, Harris MA, Bubb J, White NH. Behavior therapy for families of adolescents with diabetes: maintenance of treatment effects. Diabetes Care 2001, 24(3):441-446. 10.2337/diacare.24.3.441, 11289465.
31. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for Health Economic Evaluation 2006, New York: Oxford University Press.
32. Khdour MR, Agus AM, Kidney JC, Smyth BM, McElnay JC, Crealey GE. Cost-utility analysis of a pharmacy-led self-management programme for patients with COPD. Int J Clin Pharm 2011, 33(4):665-673. 10.1007/s11096-011-9524-z, 21643784.
33. Takemura M, Mitsui K, Itotani R, Ishitoko M, Suzuki S, Matsumoto M, Aihara K, Oguma T, Ueda T, Kagioka H, Fukui M. Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011, 6:97-104. 3048085, 21407822.
34. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006, 333(7557):15. 10.1136/bmj.38875.675486.55, 1488752, 16790458.
35. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, Knobil K, Willits LR, Yates JC, Jones PW. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009, 64(11):939-943. 10.1136/thx.2009.113662, 19703830.
36. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363(12):1128-1138. 10.1056/NEJMoa0909883, 20843247.
37. Bourbeau J. Not all self-management programs in chronic obstructive pulmonary disease have positive results: why is replication a problem?. Chron Respir Dis 2004, 1(1):5-6.
38. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, . TORCH investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789. 10.1056/NEJMoa063070, 17314337, TORCH investigators.
39. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, . UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15):1543-1554. 10.1056/NEJMoa0805800, 18836213, UPLIFT Study Investigators.
40. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD-a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009, 4:203-223. 2699821, 19554195.
41. Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, Yates JC, Calverley PM. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J 2012, 39(1):38-45. 10.1183/09031936.00194610, 21737561.
42. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, . ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013, 16(2):231-250. 10.1016/j.jval.2013.02.002, 23538175, ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force.
43. Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, Dubus JC, Magnan A, Massone F, Sanchis J, Viejo JL, Voshaar T, . Aerosol Drug Management Improvement Team The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med 2006, 100(9):1479-1494. 10.1016/j.rmed.2006.01.008, 16495040, Aerosol Drug Management Improvement Team.
44. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 2008, 102(4):593-604. 10.1016/j.rmed.2007.11.003, 18083019.
45. Health Care Insurance Board Dutch pharmacoeconomic guidelines [in Dutch]. http://www.zorginstituutnederland.nl/binaries/content/documents/zinl-www/documenten/publicaties/publications-in-english/2006/0604-guidelines-for-pharmacoeconomic-research/0604-guidelines-for-pharmacoeconomic-research/Guidelines+for+pharmacoeconomic+research.pdf, Health Care Insurance Board.
46. Makris D, Moschandreas J, Damianaki A, Ntaoukakis E, Siafakas NM, Milic Emili J, Tzanakis N. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007, 101(6):1305-1312. 10.1016/j.rmed.2006.10.012, 17112715.
47. NICE Clinical Guideline 76: Medicines adherence 2009, National Institute for Health and Clinical Excellence, http://www.nice.org.uk/nicemedia/live/11766/43042/43042.pdf.